S

Syensqo SA
XBRU:SYENS

Watchlist Manager
Syensqo SA
XBRU:SYENS
Watchlist
Price: 70.17 EUR -2.43% Market Closed
Market Cap: 7.4B EUR
Have any thoughts about
Syensqo SA?
Write Note

Gross Margin
Syensqo SA

33.3%
Current
33%
Average
23.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
33.3%
=
Gross Profit
2.8B
/
Revenue
8.5B

Gross Margin Across Competitors

Country BE
Market Cap 7.3B EUR
Gross Margin
33%
Country US
Market Cap 99.8B USD
Gross Margin
48%
Country JP
Market Cap 11.2T JPY
Gross Margin
38%
Country US
Market Cap 70.4B USD
Gross Margin
43%
Country CH
Market Cap 35.8B CHF
Gross Margin
43%
Country US
Market Cap 35B USD
Gross Margin
36%
Country CN
Market Cap 230.5B CNY
Gross Margin
15%
Country CH
Market Cap 27.9B EUR
Gross Margin
25%
Country US
Market Cap 28.6B USD
Gross Margin
42%
Country IN
Market Cap 2.4T INR
Gross Margin
43%
Country DK
Market Cap 165.6B DKK
Gross Margin
54%
No Stocks Found

Syensqo SA
Glance View

Market Cap
7.3B EUR
Industry
Chemicals

Syensqo SA stands at the forefront of the biotechnology sector, driven by a vision to revolutionize disease treatment through advanced therapeutic solutions. Founded in the heart of an innovation hub, the company specializes in developing cutting-edge synthetic biology applications aimed at enhancing drug efficacy and reducing side effects. With a dynamic pipeline populated by promising drug candidates in various stages of clinical trials, Syensqo is harnessing the power of gene editing and novel delivery systems, creating a compelling narrative of growth and potential. Its strategic partnerships with leading research institutions and pharmaceutical companies underscore a commitment to collaboration and innovation, positioning Syensqo as a promising player in an ever-evolving market. For investors, Syensqo SA embodies both opportunity and sustainability. The company’s robust intellectual property portfolio not only protects its innovations but also provides a competitive edge in emerging markets. With a dedicated team of scientists and industry veterans at the helm, Syensqo is primed to navigate the complexities of regulatory landscapes while leveraging data-driven insights to guide decision-making. As the global demand for effective healthcare solutions escalates, Syensqo's commitment to sustainable practices and ethical drug development resonates strongly with socially conscious investors. By investing in Syensqo, stakeholders are not only placing their capital in a high-growth venture but also participating in a transformative journey toward groundbreaking healthcare advancements.

SYENS Intrinsic Value
115.61 EUR
Undervaluation 39%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
33.3%
=
Gross Profit
2.8B
/
Revenue
8.5B
What is the Gross Margin of Syensqo SA?

Based on Syensqo SA's most recent financial statements, the company has Gross Margin of 33.3%.